Ken Griffin Liminal Bio Sciences Inc. Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.44 - $0.97 $5,006 - $11,037	-11,379 Reduced 30.31%	26,165 $13,000
Q3 2021 Nov 15, 2021	SELL	$2.15 - $3.92 $22,989 - $41,916	-10,693 Reduced 22.17%	37,544 $86,000
Q2 2021 Aug 16, 2021	BUY	$3.75 - $5.17 $180,888 - $249,385	48,237 New	48,237 $187,000
Q1 2021 May 17, 2021	SELL	$3.94 - $6.43 $48,056 - $78,426	-12,197 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$3.68 - $11.02 $44,884 - $134,410	12,197 New	12,197 $51,000
Q3 2020 Nov 16, 2020	SELL	$10.51 - $23.79 $118,773 - $268,850	-11,301 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$6.3 - $11.35 $71,196 - $128,266	11,301 New	11,301 $118,000

234

Ticker LMNL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,042,600
Description
Liminal BioSciences Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel small molecule drug therapeutics for inflammatory, fibrotic, and metabolic diseases in Canada and the United Kingdom. The company's lead product candidate is fezagepras (PBI-4050), which has been completed Phase I clinical trial for the trea...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.